Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Irinotecan in Second Line Small Cell Lung Cancer
NCT00005972Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2000
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, irinotecan in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Started May 2000; status: completed.
02
Drugs
gemcitabineirinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00005972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005972.